Conference Day Two: 10th November 2009

08.30 Registration And Coffee

09.00 Chair’s Welcome

Global Case Law and Judicial Update

09.15 US Case Law Update: Judicial Decisions Impacting Crystalline Forms Patent Strategy

  • Recent decisions suggesting how US courts may view crystalline form patents
  • Analysis of Abbott v. Sandoz (Fed. Cir. 2009): Crystalline Forms and Product-by-Process
  • Analysis of Sanofi-Synthelabo v. Apotex (Fed. Cir . 2008) and others
  • Analysis of Pfizer v. Apotex (Fed. Cir. 2007) and others: Salt Forms
  • Designing and implementing effective patent strategies for crystalline form patents

Raymond R. Mandra
Partner, Fitzpatrick, Cella
Harper & Scinto

10.00 UK Judicial Overview

  • Analysis of UK decisions
  • General trends in the UK decisions
  • Recent decisions suggesting how UK courts may view crystalline form patents
  • Case law affecting further decisions in the area of Crystalline forms

Alastair Wilson QC
Joint Head of Chambers
Hogarth Chambers

10.45 Networking Coffee Break

11.15 Polymorph Patenting And The Doctrine Of Inherent Anticipation: The US Perspective

  • What is Doctrine of Inherent Anticipation under US law?
  • Why inherent anticipation is a key concern to polymorph patenting based on current drug discovery process?
  • US cases dealing with inherent anticipation as it relates to polymorphic forms

Rekha Bansal
Patent Attorney

12.00 Roundtable Discussion: Process Claims Vs Product Claims

  • Identification of key claims in both areas
  • Case law in the area: Abbott vs. Sandoz patenting based on current drug discovery process?
  • The impact on internal innovators IP strategies A paper on Abbott vs. Sandoz will be provided to aid discussions.

Facilitated by Day One and Two speakers

12.45 Networking Lunch

14.00 A Generics Perspective

  • The perspective of the generic company
  • International case law – what jurisdictions matter
  • Comparison of reasoning of courts in recent high-profile cases
  • Is there convergence?

George Moore
Patent Counsel (International)

European Update

14.45 European Case Law Update

  • European case law update (England & Wales; Scotland; Ireland and EPO): the Tibolone case (Ivax & Arrow v Akzo)
  • Non pharmaceutical crystalline forms: Tate & Lyle Technology Ltd v Roquette Freres
  • Other High court decisions in the last 12 months ( Leo v Sandoz).

Andre Bourgouin
Chief IP Officer

15.30 Networking Coffee Break

16.00 European Commission, Directorate General For Competition

  • Review of the Commission's Final Report from the Pharmaceutical Sector Inquiry
  • Applicability of the EC treaty antitrust law to the IPR area (case law)
  • Competition law scrutiny according to the Final Report

Dr Filip Borkowski
DG Competition
European Commission

16.45 Chair’s Closing Remarks

17.00 Close Of Conference Day Two